A Patient with Parkinson's syndrome receives continuous levodopa to prevent what complication?

NORCET 2 -2021 (Shift-2)

Medical & Surgical Nursing

Medium

Appeared in: NORCET 2 -2021 (Shift-2)

Explanation

Levodopa therapy in Parkinson's disease aims to replenish dopamine levels in the brain.
Standard intermittent oral dosing leads to fluctuating plasma concentrations, with high peaks and low troughs.
These high peak levels can overstimulate dopamine receptors, leading to neuropsychiatric side effects, most notably psychosis and hallucinations.
Continuous levodopa infusion provides a steady, stable level of the drug, avoiding these peaks.
By maintaining stable dopaminergic stimulation, continuous therapy helps reduce the risk of developing levodopa-induced psychosis.

Option B: Agnosia is the inability to process sensory information and recognize objects, faces, or sounds. It is typically caused by damage to the brain's cortex, not the basal ganglia which are affected in Parkinson's disease.
Option C: Ataxia refers to a lack of voluntary coordination of muscle movements, often resulting in a clumsy, staggering gait. It is a hallmark sign of cerebellar dysfunction.
Option D: While anxiety is a common and significant non-motor symptom of Parkinson's disease, the primary indication for switching to a complex therapy like continuous levodopa infusion is to manage severe motor fluctuations and peak-dose side effects, not anxiety itself.

Visual 1: Graph - A comparative line graph showing the fluctuating 'peaks and troughs' of oral levodopa plasma concentration versus the smooth, stable line of continuous infusion therapy. This visually explains how continuous therapy avoids the high peaks that can trigger psychosis.
Visual 2: Diagram - An illustration of the brain highlighting the dopaminergic pathways from the substantia nigra to the striatum, showing the area of dopamine depletion in Parkinson's disease.

Clinical Relevance

Nursing practice connection: Use the key finding related to Pharmacological management of Parkinson's disease and prevention of treatment-related complications to guide bedside assessment, documentation, and the next nursing action.
Nurses play a crucial role in monitoring patients on levodopa for both motor complications (e.g., 'wearing-off' periods, dyskinesia) and neuropsychiatric side effects (e.g., confusion, hallucinations, psychosis).
Accurate documentation of symptoms and their timing in relation to medication doses is essential for the healthcare team to optimize therapy.
Patient and family education about the potential for psychosis is a key nursing responsibility to ensure early reporting and management.

How to Approach the Question

First, identify the core concepts: Parkinson's disease, levodopa, and 'continuous' administration.
Recall that levodopa is a dopamine precursor used to treat Parkinson's symptoms.
Consider the difference between standard (intermittent, oral) and 'continuous' therapy. The key difference is the stability of drug levels in the blood.
Ask yourself: What problems do fluctuating drug levels cause? This leads to thinking about 'on-off' phenomena, dyskinesias, and peak-dose side effects.
Evaluate the options. Eliminate those not associated with Parkinson's or levodopa (Agnosia, Ataxia).
Between Psychosis and Anxiety, determine which is more directly related to the 'peaks' of intermittent dosing that continuous infusion is designed to eliminate. Psychosis is a classic peak-dose side effect, making it the best fit.

Concept Tested & Keywords

Concept Tested: Pharmacological management of Parkinson's disease and prevention of treatment-related complications.
Stem keywords: Parkinson's syndrome, continuous levodopa, complication
Lead-in keywords: prevent

Qg9CZfagQP-0QaCK1ff5ay